<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01585259</url>
  </required_header>
  <id_info>
    <org_study_id>Lees_Anfibatide_Phase2</org_study_id>
    <nct_id>NCT01585259</nct_id>
  </id_info>
  <brief_title>Anfibatide Phase Ib-IIa Clinical Trial</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Multi-dose Group, Parallel Group and Placebo Controlled Phase Ib-IIa Clinical Study to Evaluate the Safety and Efficacy of Antiplatelet Thrombolysin for Injection for the Treatment of Patients With Non-ST Segment Elevation Myocardial Infarction (NSTEMI).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigate the safety and efficacy of Anfibatide in non-ST segment myocardial infarction&#xD;
      patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. This study is a phase Ib-IIa exploratory study to observe the safety of Antiplatelet&#xD;
           Thrombolysin for Injection for the treatment of non-ST segment myocardial infarction&#xD;
           (NSTEMI) patients and preliminarily evaluate the efficacy of different doses, providing&#xD;
           the theoretical basis of the phase II and III clinical study protocol.&#xD;
&#xD;
        2. To investigate the pharmacokinetics of different doses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet aggregation</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>The inhibition of ristocetin-induced platelet aggregation as measured by whole blood impedance aggregometr in vitro.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>Day 0 to day 30</time_frame>
    <description>Bleeding events classified according to the Bleeding Academic Research Consortium (BARC) .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days after treatment</time_frame>
    <description>all-cause mortality, relapse of nonfatal myocardial infarction, nonfatal stroke, second target vascular reconstructio.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Endpoints</measure>
    <time_frame>Day 0 to day 30</time_frame>
    <description>Degree of thrombocytopenia; Moderate (&lt;100,000 platelets/mm3); Severe (&lt;50,000 platelets/mm3); Extremely severe (&lt;20,000 platelets/mm3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombosis formation</measure>
    <time_frame>48 hours after infusion during operation</time_frame>
    <description>Thrombosis formation after stent implantation:</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis in myocardial infraction (TIMI)</measure>
    <time_frame>day 0</time_frame>
    <description>The proportion of TIMI from grade 0 to 3 Pre -and post-PCI was evaluated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corrected TIMI frame count（CTFC）</measure>
    <time_frame>day 0</time_frame>
    <description>The values of CTFC were evaluated and compared between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TIMI myocardial perfusion grade （TMBG）</measure>
    <time_frame>day 0</time_frame>
    <description>The proportion of TMPG from grade 0 to 3 Pre -and post-PCI was evaluated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Non-ST Segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Anfibatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bolus injection will be finished in 5 minutes immediately when the guidewire passes through the first stenosed vessel; bolus injection of different doses+0.002IU/kg/h intravenous infusion for 48h</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Bolus injection will be finished in 5 minutes immediately when the guidewire passes through the first stenosed vessel; bolus injection of different doses+0.002IU/kg/h intravenous infusion for 48h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anfibatide</intervention_name>
    <description>Snake venom</description>
    <arm_group_label>Anfibatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 18-70 years;&#xD;
&#xD;
          2. Laboratory tests show increase of the markers of myocardial damage (CK-MB,CTnI), or&#xD;
             reduction after increase, with at least one values exceeding the 99th percentile of&#xD;
             the upper limit of the reference value;&#xD;
&#xD;
          3. Ischemia symptoms (ischemic chest pain lasts for over 15 minutes, little release after&#xD;
             taking nitroglycerin sublingually) or a new myocardial ischemia on&#xD;
             electrocardiogram(ECG), i.e. a new ST-T variation (a new or transient depression of ST&#xD;
             segment by over 0.1mV, or T-wave inversion≥0.2mV);&#xD;
&#xD;
          4. Patients receive PCI after coronary angiography;&#xD;
&#xD;
          5. Patients, or their family or guardian give signed informed consent forms.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe unstable hemodynamics who should receive urgent PCI;&#xD;
&#xD;
          2. Patients with untreated hypertension (SBP&gt;180 mmHg or DBP &gt;110mmHg) and hypotension&#xD;
             shock (SBP&lt;90mmHg/80mmHg for over 30min);&#xD;
&#xD;
          3. Investigator considers patients need to use GPIIb/IIIa receptor antagonists during the&#xD;
             study period;&#xD;
&#xD;
          4. After coronary angiography, the number of stenosed vessels &gt;2；lesions in left main&#xD;
             branch, severe calcification and artery graft lesions;&#xD;
&#xD;
          5. Patients with heart function in decompensatory phase (Killip grade 3-4) or cardiac&#xD;
             shock;&#xD;
&#xD;
          6. Patients with malignant arrhythmia, e.g. the third-degree atrioventricular block,&#xD;
             ventricular tachycardia or fibrillation ventricular;&#xD;
&#xD;
          7. Patients with severe hepatic or renal dysfunction, with serum aspartate&#xD;
             transaminase(AST) and alanine transaminase (ALT) exceeding 1.5 times the upper limit&#xD;
             of reference values, creatinine clearance &lt;30ml/min or serum creatinine ≥200μmol/L or&#xD;
             2.5mg/dl;&#xD;
&#xD;
          8. Patients who have received PCI in the past six months;&#xD;
&#xD;
          9. Patients who have received coronary artery bypass grafting (CABG) previously;&#xD;
&#xD;
         10. Patients who have received invasive operation in the past 3 months;&#xD;
&#xD;
         11. Patients who have suffered from ischemic stroke or transient ischemic attack (TIA) in&#xD;
             the past 6 months, or patients with past history of hemorrhagic stroke;&#xD;
&#xD;
         12. Patients who need a long-term treatment of oral anticoagulants (such as warfarin);&#xD;
&#xD;
         13. Patients with active peptic ulcer, or other diseases of hemorrhagic tendency;&#xD;
&#xD;
         14. Patients with disease of coagulation disorder;&#xD;
&#xD;
         15. Hematology test shows platelet count &lt;100,000mm3,or hemoglobin&lt;100g/L;&#xD;
&#xD;
         16. Women in pregnant or lactation period, or women of child-bearing age do not take&#xD;
             efficient contraception measures;&#xD;
&#xD;
         17. Patients with an allergic constitution;&#xD;
&#xD;
         18. Patients who is participating in other clinical trials;&#xD;
&#xD;
         19. Patients who do not give a signed informed consent forms;&#xD;
&#xD;
         20. Patients who are not suitable to enroll in the trial according to the investigator's&#xD;
             judgement.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University First hospiatl</name>
      <address>
        <city>Beijing</city>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>April 24, 2012</study_first_submitted>
  <study_first_submitted_qc>April 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2012</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>anti-platelet;</keyword>
  <keyword>safety;</keyword>
  <keyword>efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

